Autoimmune Diseases
Page 1 • 2 itemsGain critical insights into global autoimmune disease drug development, market trends, and regulatory landscapes. Inform your pharma strategy.
InnoCare Pharma Begins Phase III Trial of Orelabrutinib for Systemic Lupus Erythematosus Treatment
InnoCare Pharma doses first patient in Phase III trial testing BTK inhibitor orelabrutinib for systemic lupus erythematosus, marking key milestone.
Nkarta Receives FDA Approval for Outpatient NKX019 Dosing in Autoimmune Disease Treatment
Nkarta secures FDA agreement for outpatient NKX019 dosing, expanding access to community rheumatology centers and reducing patient treatment burden.